NO993825L - Formulation of stabilized cationic transfection agents / nucleic acid particles - Google Patents

Formulation of stabilized cationic transfection agents / nucleic acid particles

Info

Publication number
NO993825L
NO993825L NO993825A NO993825A NO993825L NO 993825 L NO993825 L NO 993825L NO 993825 A NO993825 A NO 993825A NO 993825 A NO993825 A NO 993825A NO 993825 L NO993825 L NO 993825L
Authority
NO
Norway
Prior art keywords
nucleic acid
formulation
acid particles
transfection agents
cationic transfection
Prior art date
Application number
NO993825A
Other languages
Norwegian (no)
Other versions
NO993825D0 (en
Inventor
Joul Crouzet
Bruno Pitard
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9503492&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO993825(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of NO993825D0 publication Critical patent/NO993825D0/en
Publication of NO993825L publication Critical patent/NO993825L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention concerns a composition containing stabilised particles of cationic transfection agent(s)/nucleic acid complexes characterised in that it includes besides said transfection agent and nucleic acid at least a non-ionic surfactant in sufficient amount for preventing the aggregation of the particles in course of time. In a preferred embodiment, the surfactant is a polyoxyalkylene or a derivative thereof.
NO993825A 1997-02-10 1999-08-09 Formulation of stabilized cationic transfection agents / nucleic acid particles NO993825L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9701467A FR2759298B1 (en) 1997-02-10 1997-02-10 FORMULATION OF CATIONIC TRANSFECTING AGENT (S) / NUCLEIC ACID PARTICLES
PCT/FR1998/000222 WO1998034648A1 (en) 1997-02-10 1998-02-06 Formulation of stabilised cationic transfection agent(s)/nucleic acid particles

Publications (2)

Publication Number Publication Date
NO993825D0 NO993825D0 (en) 1999-08-09
NO993825L true NO993825L (en) 1999-08-09

Family

ID=9503492

Family Applications (1)

Application Number Title Priority Date Filing Date
NO993825A NO993825L (en) 1997-02-10 1999-08-09 Formulation of stabilized cationic transfection agents / nucleic acid particles

Country Status (20)

Country Link
EP (1) EP1007097B1 (en)
JP (1) JP2001511171A (en)
KR (1) KR20000070914A (en)
AT (1) ATE206932T1 (en)
AU (1) AU737720B2 (en)
BR (1) BR9807563A (en)
CA (1) CA2278665A1 (en)
CZ (1) CZ282199A3 (en)
DE (1) DE69802102T2 (en)
DK (1) DK1007097T3 (en)
ES (1) ES2166146T3 (en)
FR (1) FR2759298B1 (en)
GR (1) GR3036919T3 (en)
HU (1) HUP0001720A3 (en)
IL (1) IL130765A0 (en)
NO (1) NO993825L (en)
PT (1) PT1007097E (en)
SK (1) SK282685B6 (en)
WO (1) WO1998034648A1 (en)
ZA (1) ZA981034B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6359054B1 (en) * 1994-11-18 2002-03-19 Supratek Pharma Inc. Polynucleotide compositions for intramuscular administration
AU768542C (en) * 1998-04-08 2004-06-17 Celltech R & D Limited Lipids
WO2000003683A2 (en) * 1998-07-20 2000-01-27 Inex Pharmaceuticals Corporation Liposomal encapsulated nucleic acid-complexes
BR0108959A (en) * 2000-03-03 2003-10-14 Valentis Inc Improved poloxamer or poloxamine compositions for nucleic acid delivery
GB0009201D0 (en) * 2000-04-14 2000-05-31 Univ Nottingham Cationic polymer - Nucleic acid complexes and methods of making them
US20020091242A1 (en) 2000-10-11 2002-07-11 Michel Bessodes Acid-sensitive compounds, their preparation and uses
ATE503463T1 (en) * 2000-10-20 2011-04-15 Vical Inc GENE DELIVERY FORMULATIONS FOR TREATING ISCHEMIC CONDITIONS
EP1232758A1 (en) * 2001-02-19 2002-08-21 Aventis Pasteur Polynucleotide formulated for improved intracellular transfer
CA3031270A1 (en) 2004-03-03 2005-12-22 Revance Therapeutics, Inc. Compositions and methods for topical diagnostic and therapeutic transport
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
EP1861112A4 (en) 2005-03-03 2009-07-22 Revance Therapeutics Inc Compositions and methods for topical application and transdermal delivery of botulinum toxins
JP4653242B1 (en) 2010-02-12 2011-03-16 ナノキャリア株式会社 Particulate pharmaceutical composition

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1181937A3 (en) * 1994-08-09 2004-02-04 Cytrx Corporation Novel vaccine adjuvant and vaccine
WO1996030051A1 (en) * 1995-03-31 1996-10-03 Genetic Therapy, Inc. Use of surfactants for introducing genetic material into lung cells
US6120794A (en) * 1995-09-26 2000-09-19 University Of Pittsburgh Emulsion and micellar formulations for the delivery of biologically active substances to cells

Also Published As

Publication number Publication date
AU737720B2 (en) 2001-08-30
EP1007097A1 (en) 2000-06-14
EP1007097B1 (en) 2001-10-17
HUP0001720A1 (en) 2000-09-28
CZ282199A3 (en) 1999-10-13
JP2001511171A (en) 2001-08-07
ATE206932T1 (en) 2001-11-15
KR20000070914A (en) 2000-11-25
IL130765A0 (en) 2001-01-28
BR9807563A (en) 2000-02-01
ES2166146T3 (en) 2002-04-01
DE69802102T2 (en) 2002-03-14
HUP0001720A3 (en) 2001-10-29
FR2759298B1 (en) 1999-04-09
NO993825D0 (en) 1999-08-09
DK1007097T3 (en) 2002-02-11
SK108299A3 (en) 2000-05-16
WO1998034648A1 (en) 1998-08-13
ZA981034B (en) 1998-08-11
GR3036919T3 (en) 2002-01-31
AU6298798A (en) 1998-08-26
DE69802102D1 (en) 2001-11-22
PT1007097E (en) 2002-04-29
FR2759298A1 (en) 1998-08-14
CA2278665A1 (en) 1998-08-13
SK282685B6 (en) 2002-11-06

Similar Documents

Publication Publication Date Title
NO993825D0 (en) Formulation of stabilized cationic transfection agents / nucleic acid particles
IL172835A0 (en) A composition for stabilizing active protein ingredients in pharmaceutical composition containing at least 2 amino acids
EP0911039A3 (en) Drug-resin complexes stabilized by chelating agents
PT1123120E (en) MEDICINAL FORMULATION IN AEROSOL
ATE383169T1 (en) COMPONENT AND COMPOSITIONS FOR ADMINISTRATION OF ACTIVE INGREDIENTS
TR199501321A2 (en) Pharmaceutical compositions.
HK1028548A1 (en) Formulations for hydrophobic pharmaceutical agents
IL213594A0 (en) Uses of pharmaceutical compositions comprising an alkaoid3
WO2000032186A3 (en) Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents
WO2000050046A8 (en) Stabilized oral pharmaceutical composition containing iodide and iodate and method
IT1314185B1 (en) PHARMACEUTICAL COMPOSITION FOR ADMINISTRATION OF SUBSTANCES ACTIVELY SOLUBLE IN AQUEOUS MEDIA
MXPA04001007A (en) Invert emulsion containing dhea.
ATE245028T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING TRIMEGESTONE
BR9811985A (en) Dosing device
WO2002083891A3 (en) Nucleic acids for inhibiting hairless protein expression and methods of use thereof
TNSN97173A1 (en) PEPTIDE ANALOGS OF LH-RH, THEIR USES AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME.
MX9806123A (en) Cleansing composition comprising color stabilizer(s) and surfactant(s)
WO2000021577A3 (en) Compositions
HUP0202378A3 (en) Surfactant mixture, emulsion containing thereof structured surfactant composition and detergent composition
WO1998023260A3 (en) Non-ionic surfactant vesicles as a delivery agent for nucleic acid
EP0891778A3 (en) Agents for the prevention and/or treatment of radiation-induced disorders
Kamioka Dynamics and kinetics of oxidation of semiconductor surfaces
MX9603741A (en) Sustained delivery composition.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application